# Gastro-intestinal system - BNF chapter 1

Source: https://www.rightdecisions.scot.nhs.uk/dgrefhelp-nhs-dumfries-galloway/dg-formulary/gastro-intestinal-system-bnf-chapter-1/
Fetched: 2026-02-23

## 1. Chronic bowel disorders

Local Gluten Free Formulary available at Gluten Free Services - NHS Dumfries and Galloway

**NICE NG129:** Crohn’s disease: management

**NICE NG130:** Ulcerative colitis: management

### Crohn’s Disease

#### Acute Exacerbation of Crohn’s Disease

- Prednisolone tablets ✓ First Choice
- Methylprednisolone IV – hospital only
- Budesonide (Budenofalk® E/C Capsules, E/C Granules, Entocort® Modified Release Tablets)

#### Add on Treatment / Maintenance of Remission – Drugs Affecting the Immune Response

- Azathioprine tablets ✓ First Choice– unlicensed indication ✓ Specialist Initiation Only
- Mercaptopurine Tablets – unlicensed indication ✓ Specialist Initiation Only – use branded Hanixol
- Methotrexate (specialist initiation only)

### Ulcerative Colitis

Treatment of Acute Mild-Moderate Ulcerative Colitis - the severity and extent of the disease should be considered when choosing the route of administration.

#### Ulcerative Proctitis

- Mesalazine 1g Suppositories (Salofalk®) ✓ First Choice
- Budesonide 2mg foam enema
- Budesonide 4mg suppository

If not managed on rectal preparation add mesalazine 3mg MR Granules (Salofalk)

#### Rectosigmoid

- Mesalazine 1g Foam Enema (Salofalk®) ✓ First Choice
- Budenofalk 2mg foam enema

If not managed on rectal preparation add mesalazine 3mg MR Granules (Salofalk®)

#### Disease above the Rectosigmoid

- Mesalazine 2g Liquid enema (Salofalk®) ✓ First Choice
- Budesonide 2mg foam enema
- Mesalazine 3mg MR Granules (Salofalk®) ✓ First Choice

#### Pancolitis

- Octasa 800mg tablets ✓ First Choice

#### Severe Exacerbation

- Prednisolone tablets ✓ First Choice
- Budesonide (Cortiment®) 9mg prolonged release tablets - Restricted for use in patients with UC who present with active left-sided disease and/or proctosigmoiditis who are not suitable for oral prednisolone, as an alternative to budesonide rectal formulations or off-label oral budesonide

#### Other Corticosteroids

- Budesonide (Jorveza) 1mg orodispersible tablets – ✓ Specialist Initiation Only for the treatment of eosinophilic oesophagitis in adults (older than 18 years of age) who have been unsuccessfully treated with proton pump inhibitors..



#### Immunosuppressants

**** Adalimumab – ✓ Specialist Use Only, prescribe by brand ****

Amgevita® SC - preferred biosimilar

Crohn’s disease: For the treatment of severe, active Crohn’s disease in adults whose disease has not responded to conventional therapy (including immunosuppressive and/or corticosteroid treatments) or who are intolerant of or have contraindications to such therapies, in line with NICE MTA 187.

Ulcerative colitis : Use in the treatment of moderately to severely active ulcerative colitis in adults is restricted to those patients whose disease has responded inadequately to conventional therapy, including corticosteroids, Mercaptopurine and Azathioprine, or who cannot tolerate, or have medical contraindications for such therapies.



**** Infliximab - ✓ Specialist Use Only, prescribe by brand ****

Remsima® IV/SC– preferred biosimilar.

Crohn’s disease: Infliximab is formulary for the treatment of severe active Crohn’s disease in adults whose disease has not responded to conventional therapy (including immunosuppressive and/or corticosteroid treatments) or who are intolerant of or have contraindications to conventional therapy, in line with NICE MTA 186.

Ulcerative colitis: Treatment of moderately to severely active ulcerative colitis in adults is restricted to those patient whose disease has responded inadequately to conventional therapy, including corticosteroids, mercaptopurine and azathioprine, or who cannot tolerate, or have medical contraindications for such therapies.



**** Ustekinumab - ✓ Specialist Use Only, prescribe by brand **Wezenla® SC▼ - preferred biosimilar**

**Crohn’s disease:****The treatment of adults with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or where intolerant to either conventional therapy or a TNF alpha antagonist or have medical contraindication to such therapies.****Ulcerative colitis: For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.**

**** Upadacitinib Tablets (Rinvoq®) – ✓ Specialist Use Only ****

Crohn’s disease: ******For the treatment of adult patients with moderately to severely active Crohn’s disease (CD) who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent, or for whom such therapies are not advisable.****Ulcerative colitis: For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.**

**** Filgotinib Tablets (Jyseleca®) – ✓ Specialist Use Only ****

**Ulcerative colitis: for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.**

**** Tofacitinib Tablets (Xeljanz®) – ✓ Specialist Use Only ****

**Ulcerative colitis: For the treatment of adults with moderately to severely active ulcerative colitis is restricted to specialist use in patients who have had an inadequate response, lost response, or were intolerant to either conventional therapy and a biologic agent.**

**** Mirikizumab IV/SC (Omvoh®) – ✓ Specialist Use Only ****

**Ulcerative colitis: For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.**

**** Risankizumab IV/SC (Skyrizi®) – ✓ Specialist Use Only ****

**Crohn’s disease: For the treatment of patients 16 years and older with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy, or if such therapies are not advisable.Ulcerative colitis: For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy. (Business Case not yet through ADTC)**

**** Vedolizumab IV/SC (Entyvio®) – ✓ Specialist Use Only ****

**Crohn’s disease: For the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist.Ulcerative colitis: For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist.**

NICE CG61: IBS in adults diagnosis and management

### Antispasmodics

- Hyoscine Butylbromide Tablets ✓ First Choice
- Mebeverine 135mg Tablets
- Peppermint oil capsules (Reserved for symptoms of bloating). Prescribe as Mintec®

#### Laxatives – Guanylate Cyclase c receptor agonists

Linaclotide – ✓ Specialist Initiation Only for IBS with constipation as predominant feature

## 2. Constipation and bowel cleansing

- Moviprep® ✓ First Choice
- Picolax®

### Bulk forming laxatives

- Ispaghula Husk

### Osmotic laxatives

- Macrogol 3350 sachets (Laxido®, Laxido Paediatric®) ✓ First Choice
- Lactulose Solution
- Phosphate enema (first line rectal formulation) ✓ First Choice

### Faecal softeners

- Docusate Sodium Capsules

### Stimulant laxatives

- Bisacodyl Tablets ✓ First Choice
- Glycerol Suppositories ✓ First Choice
- Senna tablets

## 3. Diarrhoea (acute)

### Diarrhoea (Acute)

- Oral Rehydration Sachets (Dioralyte®) – for acute diarrhoea ✓ First Choice
- Loperamide 2mg Capsules
- Codeine Phosphate Tablets

## 4. Disorders of gastric ulceration and ulceration

NICE CG184: Gastro-oesophageal reflux disease and dyspepsia in adults

### Antacids

- Peptac® Suspension (first line compound alginates and proprietary indigestion preparation) ✓ First Choice
- Gaviscon Double Action® (only available as mint)
- Co-Magaldrox (Mucogel®) First line antacid with Simeticone. ✓ First Choice

#### Paediatrics

Gaviscon® Infant Sachets - One dose is equivalent to half a dual sachet.

### H2-receptor antagonists

- Famotidine ✓ First Choice

### Proton pump inhibitors

- MHRA Drug Safety Update (2014): PPIs and hypomagnesaemia
- MHRA Drug Safety update (2015): PPIs and SCLE
- MHRA Drug Safety Update: PPIs in long term use: increased risk of fracture
- MHRA Drug Safety Update (2014): Clopidogrel and PPIs interaction

### Helicobacter pylori Eradication

#### No penicillin allergy:

- Omeprazole 20mg Capsules or lansoprazole 30mg capsules twice daily
- Amoxicillin 1g twice daily
- Clarithromycin 500mg twice daily or Metronidazole 400mg twice daily. (Treatment choice should take into account previous treatment with clarithromycin or metronidazole)

#### Penicillin allergy

##### Oral first line for 7 days:

- Omeprazole 20mg or lansoprazole 30mg capsules twice daily plus
- Clarithromycin 500mg twice daily, and
- Metronidazole 400mg twice a day

## 6. Gastro-intestinal smooth muscle spasm

See Section 1.4 – Antispasmodics

## 7. Liver disorders and related conditions

### Bile acids

- Colestyramine Sachets/Colestyramine Light Sachets. Please note locally Colestid is preferred second choice over Cholestagel. Local agreement in place ✓ Specialist Initiation Only

### Primary Biliary Cholangitis

- Obeticholic acid ✓ Specialist Initiation Only
- Ursodeoxycholic acid

### Hepatic Encephalopathy

- Rifaximin tablets ✓ Specialist Initiation Only
- Lactulose - to inhibit ammonia production in the intestine / accelerate defaecation

## 8. Obesity

- Diet and lifestyle changes ✓ First Choice
- Orlistat

## 9. Rectal and anal disorders

- Anusol HC
- Diltiazem 2% ✓ Specialist Initiation Only
- Rectogesic® 0.4% ointment ✓ Specialist Initiation Only as per local protocol

- Scheriproct® ointment/suppositories ✓ First Choice

## 10. Reduced exocrine secretions

- Creon® Capsules

Note ongoing intermittent supply issues see DGRefHelp

## 11. Stoma care

- See local stoma guidance - Under review

---
## Editorial Information

- **Last reviewed:** 25/04/2025
- **Next review date:** 30/04/2027
- **Author(s):** Formulary subgroup of ADTC.
- **Version:** 1.0
- **Approved By:** ADTC
